Drugs Made In America Acquisition Corp. Units (DMAAU) — Working Capital to Net Assets Ratio
Drugs Made In America Acquisition Corp. Units (DMAAU) has a Working Capital to Net Assets ratio of -0.2% as of March 2026. Working capital of $-363.98K (current assets of $12.19K minus current liabilities of $376.17K) is measured against net assets of $232.64 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Drugs Made In America Acquisition Corp. to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Drugs Made In America Acquisition Corp. Units Working Capital to Net Assets (2024–2025)
This chart shows how Drugs Made In America Acquisition Corp. Units's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the ratio stands at -0.2%, reflecting working capital of $-363.98K against net assets of $232.64 Million USD. See Drugs Made In America Acquisition Corp. (DMAAU) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Drugs Made In America Acquisition Corp. Units (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Drugs Made In America Acquisition Corp. Units from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see DMAAU market cap.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -0.2% | $-363.98K | $232.64 Million | $12.19K | $376.17K | ▲ +1713.3 pp |
| 2024 | -1713.4% | $4.20K | $-244.85 | $4.99K | $795.67 | — |